TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15321 · Dec 9

#go#game_engine#game_engine_2d#game_engine_3d#game_engine_development#game_engine_framework#gameengine#go#golang Kaiju Engine is a fast, modern 2D/3D game engine written in Go and powered by Vulkan, designed for simplicity and high performance. It runs on Windows, Linux, Android, and is working on Mac support. Kaiju offers much faster rendering speeds and lower memory use than popular engines like Unity, making game development quicker and more efficient. It uses Go’s garbage collector to help prevent common programming errors, improving stability. You can write games directly in Go, and the engine supports local AI integration and a flexible UI system using HTML/CSS. Although the editor is still in development, the engine itself is production-ready, offering a powerful tool for developers who want speed and simplicity. https://github.com/KaijuEngine/kaiju

Results

2 similar posts found

Search: #clinicaltrials

当前筛选 #clinicaltrials清除筛选
Venture Village Wall 🦄

@venturevillagewall · Post #3449 · 12/19/2024, 01:55 PM

SleepCogni Secures $380K Funding SleepCogni has raised $380.86K in funding as of December 17, 2024. The sleep aid device aims to empower users to enhance their sleep quality. Positive feedback from clinical trials highlights the effectiveness of the device in promoting relaxation and reducing anxiety for better sleep. #SleepCogni#Funding#SleepAid#HealthTech#ClinicalTrials

Venture Village Wall 🦄

@venturevillagewall · Post #3557 · 12/20/2024, 09:32 AM

Spine BioPharma Raises $13.51M Spine BioPharma has successfully closed a funding round totaling $13.51 million, announced on December 18, 2024. For more details, visit their official site: Spine BioPharma. #SpineBioPharma#Funding#BioPharma#Investment#Healthcare#LifeSciences#VentureCapital#Startup#ClinicalTrials#MedicinalResearch#Pharma#Innovations#Tech#Biotechnology#Market#Earnings#Growth#Investors#Equity